OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

219

Enrollment

INDUSTRY

Sponsor class

Stopped due to COVID-19

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: OSE2101
DRUG: Docetaxel
DRUG: Pemetrexed

Sponsor

OSE Immunotherapeutics